We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$4.3B 37.57%
34,130,161
+20,150
+0.1% +$2.56M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.37B 20.68%
45,725,556
+10,000
+0% +$636K
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.04B 9.1%
8,553,864
+2,009,734
+31% +$234M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$720M 6.3%
25,819,768
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.9B
$536M 4.69%
5,905,673
+1,099,190
+23% +$100M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$449M 3.92%
13,779,866
+8,884
+0.1% +$281K
DBVT
7
DBV Technologies
DBVT
$914M
$197M 1.72%
550,956
– –
ONC
8
BeOne Medicines Ltd
ONC
$42.4B
$165M 1.45%
3,673,175
– –
NGNE icon
9
Neurogene
NGNE
$773M
$154M 1.35%
546,708
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
$104M 0.91%
4,804,604
+222,222
+5% +$5.07M
AMRN
11
Amarin Corp
AMRN
$298M
$91.4M 0.8%
1,133,475
+652
+0.1% +$40.5K
AAAP
12
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$86.7M 0.76%
2,221,706
– –
ONCE
13
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$78.8M 0.69%
1,318,341
– –
NVTA
14
DELISTED
Invitae Corporation
NVTA
$69.7M 0.61%
7,288,300
– –
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.44B
$65.1M 0.57%
11,716,784
– –
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$58.8M 0.51%
503,231
– –
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
$51.4M 0.45%
625,000
+125,000
+25% +$9.37M
EXEL icon
18
Exelixis
EXEL
$13.4B
$51.3M 0.45%
2,082,012
-521,557
-20% -$11M
ASND icon
19
Ascendis Pharma A/S
ASND
$16.6B
$48.6M 0.43%
1,751,463
+400,000
+30% +$10.6M
HRTX icon
20
Heron Therapeutics
HRTX
$60.4M
$38.6M 0.34%
2,783,569
– –
SGMO
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$36.2M 0.32%
4,113,376
-417,525
-9% -$2.68M
BLUE
22
DELISTED
bluebird bio
BLUE
$31.7M 0.28%
23,271
-3,860
-14% -$4.66M
ARAV
23
DELISTED
Aravive, Inc. Common Stock
ARAV
$29M 0.25%
276,766
– –
NBIX icon
24
Neurocrine Biosciences
NBIX
$15.5B
$28.4M 0.25%
616,682
-278,740
-31% -$13.5M
CERS icon
25
Cerus
CERS
$566M
$25.7M 0.22%
10,241,943
-2,811,332
-22% -$9M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2017 Portfolio in Review

As of Q2 2017, Julian Baker held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Julian Baker's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Julian Baker fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Julian Baker's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Julian Baker opened 6 new positions and closed 4 in Q2 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.